Catalytic antibodies in patients with systemic lupus erythematosus - Inserm - Institut national de la santé et de la recherche médicale Accéder directement au contenu
Article Dans Une Revue European Journal of Rheumatology Année : 2018

Catalytic antibodies in patients with systemic lupus erythematosus

Vandana Pradhan
  • Fonction : Auteur
  • PersonId : 1084596
Pallavi Pandit
  • Fonction : Auteur
Prathamesh Surve
  • Fonction : Auteur
Maxime Lecerf
Anjali Rajadhyaksha
  • Fonction : Auteur
Milind Nadkar
  • Fonction : Auteur
Prasad V Khadilkar
  • Fonction : Auteur
Durga A Chougule
  • Fonction : Auteur
Aalaap Naigaonkar
  • Fonction : Auteur
Jagadeesh Bayry
Kanjaksha Ghosh
  • Fonction : Auteur
Srini V Kaveri
  • Fonction : Auteur

Résumé

Objective: Antibodies with catalytic (hydrolytic) properties to DNA or RNA have been reported in systemic lupus erythematosus (SLE). However, it is well known that ethnicity plays an important role in the presentation of SLE and severity of the disease; hence, these data may not truly represent a general feature of all SLE patients. Therefore, we have analyzed the hydrolyzing activity of immunoglobulin G (IgG) of SLE patients from the Indian population with an aim to decode whether the catalytic antibody response represents part of an active disease process. Methods: IgGs were isolated from the sera of 72 consecutive patients diagnosed with SLE. As a control, IgGs from healthy donors were used. The catalytic activity of IgG was measured by PFR-MCA and affinity-linked oligonucleotide nuclease assay. Results: IgGs from patients with SLE from the Indian subcontinent displayed significantly higher hydrolysis rates of both the surrogate substrate, PFR-MCA, and the DNA than IgG from healthy individuals. Intergroup comparisons of the IgG-PFR-MCA interactions with clinical manifestations of the disease demonstrated a significantly increased level of hydrolysis among the patients with renal involvement who tested positive for anti-dsDNA antibodies. The PFR-MCA hydrolysis also appears to be associated with the active disease (p=0.0988, vs. inactive group). Conclusion: The prevalence of catalytic antibodies represents a general feature of SLE patients, irrespective of their origin.

Domaines

Immunologie
Fichier principal
Vignette du fichier
2018 Pradhan EJR CatAb SLE .pdf (200.43 Ko) Télécharger le fichier
Origine : Accord explicite pour ce dépôt

Dates et versions

hal-02328224 , version 1 (07-12-2020)

Identifiants

Citer

Vandana Pradhan, Pallavi Pandit, Prathamesh Surve, Maxime Lecerf, Anjali Rajadhyaksha, et al.. Catalytic antibodies in patients with systemic lupus erythematosus. European Journal of Rheumatology, 2018, 5 (3), pp.173-178. ⟨10.5152/eurjrheum.2018.17194⟩. ⟨hal-02328224⟩
65 Consultations
46 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More